SCHEMBL8452373

SCHEMBL8452373

O=C(Nc1nc[nH]n1)C1CC1c1ccc(-c2ccc(F)cc2)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 2/20 0.40
PTPN6 P29350 1/20 0.40
PTPN11 Q06124 1/20 0.40
KDM1A O60341 8/20 0.40
NPC1 O15118 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
ABL1 P00519 1/20 0.37
TCF4 P15884 1/20 0.37
CTNNB1 P35222 1/20 0.37
MAPK14 Q16539 3/20 0.37
MAOB P27338 2/20 0.37
GSK3B P49841 1/20 0.37
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 1/20 0.36
NAMPT P43490 1/20 0.36
PTPN2 P17706 1/20 0.36
CHRNA7 P36544 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8446370 0.80 KDM1A (0.45) PTPN1PTPN6PTPN11KDM1ANPC1
SCHEMBL3605976 0.79 KDM1A (0.49) PTPN1PTPN6PTPN11KDM1ANPC1
SCHEMBL3600206 0.79 KDM1A (0.49) PTPN1PTPN6PTPN11KDM1ANPC1
SCHEMBL3600203 0.79 KDM1A (0.49) PTPN1PTPN6PTPN11KDM1ANPC1
Hydrochloric Acid SCHEMBL3605053 0.78 KDM1A (0.48) PTPN1PTPN6PTPN11KDM1ANPC1
Hydrochloric Acid SCHEMBL3605051 0.78 KDM1A (0.48) PTPN1PTPN6PTPN11KDM1ANPC1
SCHEMBL8446372 0.78 DEGS1 (0.47) ABL1TCF4CTNNB1MAPK14GSK3B
SCHEMBL8465483 0.78 SCN3A (0.50) PTPN1PTPN6PTPN11NPC1GAA
SCHEMBL8453140 0.77 KDM1A (0.47) PTPN1PTPN6PTPN11KDM1AABL1
SCHEMBL8470383 0.77 HDAC1 (0.41) PTPN1PTPN6PTPN11KDM1AABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121612-B1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI SA (FR) 2014-10-01 EP disclosed
US-8299102-B2 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals SANOFI (FR) 2012-10-30 US disclosed
US-20100016278-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2010-01-21 US disclosed
WO-2008080511-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS SANOFI-AVENTIS (FR) 2008-07-10 WO disclosed
EP-1942104-A1 Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals sanofi-aventis (FR) 2008-07-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016278-A1 HETEROARYLCYCLOPROPANECARBOXAMIDES AND THEIR USE AS PHARMACEUTICALS PTGIS, TBXAS1, EDNRA PTPN1 1734/4885PTPN6 2186/4885PTPN11 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.